

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
31 January 2002 (31.01.2002)

PCT

(10) International Publication Number  
**WO 02/07718 A1**

- (51) International Patent Classification<sup>7</sup>: **A61K 31/085**,  
A61P 15/12 // C07C 43/23
- (74) Agent: **ÖHMAN, Ann-Marie**; c/o Hormos Medical Oy  
Ltd, Tykistökatu 6 A, FIN-20520 Turku (FI).
- (21) International Application Number: PCT/FI01/00414
- (22) International Filing Date: 2 May 2001 (02.05.2001)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
09/625,199 21 July 2000 (21.07.2000) US
- (71) Applicants (for all designated States except US): **HORMOS MEDICAL CORPORATION** [FI/FI]; Itäinen Pitkätie 4 B, FIN-20520 Turku (FI). **TESS DIAGNOSTICS AND PHARMACEUTICALS, INC.** [US/US]; 7689 Shadow Oaks Lane, Granite Bay, CA 95746 (US).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **HALONEN, Kaija** [FI/FI]; Niittytie 10, FIN-21290 Rusko (FI). **KANGAS, Lauri** [FI/FI]; Yrjönniityntie 21, FIN-21420 Lieto (FI). **DEGREGORIO, Michael, W.** [US/US]; 7689 Shadow Oaks Lane, Granite Bay, CA 95746 (US).
- Published:  
— with international search report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 02/07718 A1

(54) Title: METHOD FOR THE TREATMENT OF CLIMACTERIC DISORDERS IN WOMEN DURING OR AFTER THE MENOPAUSE

(57) Abstract: This invention concerns a method for the treatment of vaginal dryness or sexual dysfunction in women during or after the menopause, said method comprising administering to the woman an effective amount of the compound (deaminohydroxy)toremifene or a pharmaceutically acceptable salt or ester thereof, or a metabolite thereof.



## METHOD FOR THE TREATMENT OF CLIMACTERIC DISORDERS IN WOMEN DURING OR AFTER THE MENOPAUSE

### 5 FIELD OF THE INVENTION

This invention relates to a method for the treatment of climacteric disorders, i.e. vaginal dryness or sexual dysfunction in women during or after menopause.

10

### BACKGROUND OF THE INVENTION

15

The publications and other materials used herein to illuminate the background of the invention, and in particular, cases to provide additional details respecting the practice, are incorporated by reference.

20

25

30

During and after menopause, elderly women commonly develop symptoms which are due to estrogen deficiency. These symptoms include hot flashes, sweating, insomnia, depression, vaginal dryness, urinary incontinence, nausea, pain, osteoporosis, coronary heart disease, breast tenderness, oedema, fatigue, decreased sexual activity, as well as subsequent psychosocial problems (Payer, 1990; Rekers, 1990). In addition, estrogens are suggested to have neuroprotective effects. Thus, declining estrogen concentrations may negatively affect the mental activities of aging women (Schneider & Finch, 1997; Wickelgren, 1997). Estradiol is known to be excellent in the treatment of climacteric symptoms, and its use in the treatment of these symptoms is rapidly increasing. However, estrogens cause an increased risk of endometrial and breast cancers. It is possible to decrease the carcinogenicity of endometrial cancer by sequential progestin administration, but the risk of breast cancer is not diminished by progestins. The carcinogenicity risk limits

the length of estrogen replacement therapy, although it would be very useful to continue the therapy long term, due to the protective effects of estrogens in the bone, in the cardiovascular system, in the central nervous system, and for urinary symptoms.

5

Antiestrogens, now often referred to as "SERM"s (selective estrogen receptor modulators), have both estrogen-like and antiestrogenic properties (Kauffman & Bryant, 1995). The effects may be tissue-specific as in the case of tamoxifen and toremifene which have estrogen-like effects in the bone, partial estrogen-like effect in the uterus and liver, and pure antiestrogenic effect in breast cancer. Raloxifene and droloxifen are similar to tamoxifen and toremifene, except that their antiestrogenic properties dominate. Based on the published information, all SERMs are more likely to cause menopausal symptoms than to prevent them. They have, however, other important benefits in elderly women: they decrease total and LDL cholesterol, thus diminishing the risk of cardiovascular diseases, and they may prevent osteoporosis and inhibit breast cancer growth in postmenopausal women. There are also almost pure antiestrogens under development. They are mainly aimed at the treatment of breast cancer (Wakeling & Bowler, 1988).

20

The compound (deaminohydroxy)toremifene, which also is known under the code FC-1271a, has relatively weak estrogenic and antiestrogenic effects in the classical hormonal tests (Kangas, 1990). It has antiosteoporosis actions and it decreases total and LDL cholesterol levels in both experimental models and in human volunteers (International patent publications WO 96/07402 and WO 97/32574). It also has antitumor activity in an early stage of breast cancer development in an animal breast cancer model. The effect of antiestrogens on climacteric symptoms has not been studied earlier. FC-1271a is the first SERM which has been shown to have beneficial effects in age-related syndromes in healthy women.

30

## SUMMARY OF THE INVENTION

The invention concerns a method for the treatment of vaginal dryness or sexual dysfunction in women during or after the menopause, said method comprising administering to the woman an effective amount of the compound (deaminohydroxy)toremifene or a pharmaceutically acceptable salt or ester thereof, or a metabolite thereof.

The invention concerns also the use of the compound (diaminohydroxy)toremifene or a pharmaceutically acceptable salt or ester or metabolite thereof for the manufacture of a pharmaceutical composition for the treatment of vaginal dryness or sexual dysfunction in women during or after the menopause.

## BRIEF DESCRIPTION OF THE DRAWINGS

Figures 1A to 1D show changes (from start to 12 weeks' treatment) in the karyopyknosis index for superficial cells of the vaginal epithelium for the individuals treated daily with 30 mg FC-1271a (1A), 60 mg FC-1271a (1B), 90 mg FC-1271a (1C), and 60 mg raloxifene (1D).


Figure 2 shows the effect of 30 mg, 60 mg and 90 mg daily doses of FC-1271a and raloxifene (daily dose 60 mg) on vaginal dryness, assessed as the individuals' subjective estimates.

## DETAILED DESCRIPTION OF THE INVENTION

This invention relates to the use of the estrogen receptor modulator FC-1271a, (deaminohydroxy)toremifene, in elderly women suffering from vaginal dryness or sexual dysfunction. FC-1271a, one of the main

metabolites of toremifene, is known to be an estrogen agonist and antagonist (Kangas, 1990; International patent publications WO 96/07402 and WO 97/32574).

The formula of FC-1271a (or (deaminohydroxy)toremifene) is



The compound shall be understood to also include its geometric isomers and stereoisomers.

- 15 The term "metabolite" shall be understood to cover any (deaminohydroxy)toremifene metabolite already discovered or to be discovered. As examples of such metabolites can be mentioned the oxidation metabolites mentioned in Kangas (1990) on page 9 (TORE VI, TORE VII, TORE XVIII, TORE VIII, TORE XIII), especially TORE VI and TORE
- 20 XVIII, and other metabolites of the compound.

The new and surprising effect of this compound was found in a clinical study. In this study, raloxifene (60 mg/day) or FC-1271a at different doses were given to elderly female volunteers for a period of 3 months. At the dose levels

25 of 30, 60 and 90 mg daily, a significant decrease in vaginal dryness was observed. An improved sexual activity was also reported. These properties are new and unique among the known selective estrogen receptor modulators (SERMs) and indicate that FC-1271a at the doses from 25 mg to slightly lower than 100 mg daily, particularly 30 to 90 mg daily, can be successfully

30 used to alleviate vaginal dryness and sexual dysfunction of elderly women.

Furthermore, FC-1271a has a superior profile of estrogenic and antiestrogenic effects when compared to any known antiestrogen or SERM compound.

The compound FC-1271a has been found to alleviate sexual dysfunction and to increase the sexual activity. Types and causes of female sexual dysfunction are 1) Desire disorders, 2) Arousal disorders, 3) Orgasmic disorders and 4) Painful intercourse (dyspareunia). Most of these are due to hormonal reasons, especially to reduced estrogen and testosterone concentrations. Vaginal dryness is one of the main causes of female sexual dysfunction and will typically develop after the menopause when the estrogen concentrations decrease. Typically this leads to painful intercourse, which indirectly may influence on any type of sexual dysfunction, including psychological causes. In elderly women vaginal dryness is often the main reason for decreased sexual activity. (Spector IP, Carey MP: Incidence and prevalence of sexual dysfunctions: a critical review of the empirical literature. Archives of Sexual Behaviour 19: 389-408, 1990).

Estrogens and testosterone are useful pharmaceutical treatments of vaginal dryness and it is not surprising that pure antiestrogens like raloxifene cause vaginal dryness. Subsequently, the patients are not satisfied with the treatment which causes painful intercourse and will stop the therapy.

The compound can be administered by various routes of which oral or transdermal administration routes are the most preferable.

25

Suitable preparation forms include for example tablets, capsules, granules, powders, suspensions, syrups and transdermal ointments or gels.

## EXPERIMENTS

A clinical phase I-II study was carried out to study the effects of FC-1271a on endometrial thickness, endometrial pathology, (biopsy taken by curettage as described by Vuopala et al, 1982) and cervical smear in healthy postmenopausal female volunteers in the age range 55 to 69 years.

Tolerability and pharmacokinetics were also assessed. Raloxifene (60 mg daily) was used as reference. FC-1271a was given perorally at the doses of 30, 60 and 90 mg daily. There were 29 volunteers at each dose level, as well as in the raloxifene group. FC-1271a was administered in gelatine capsules containing either 30, 60 or 90 mg of FC-1271a. The thickness of the endometrium was evaluated by ultrasonography using a Hitachi EUB-405 instrument. The vaginal epithelium was assessed by karyopyknosis index which is a well known assessment method among the skilled persons. In this method, the vaginal fraction of the cervical smears is estimated as the percentage of the number of cells from different layers: the parabasal cell layer; the intermediate cell layer; and the superficial cell layer. Estrogenicity is seen by a shift towards superficial cell fraction. In postmenopausal women this fraction usually is close to zero and estradiol treatment increases the fraction close to 100. Samples were taken before and after the treatment (at 3 months).

The vaginal dryness symptoms were also assessed by using a visual analogue scale where the volunteers themselves recorded their subjective estimates. The scale is based on a 100-mm line on paper. The left end represents no symptom and the right end the worst possible symptom. The change from pretreatment to 3 months estimates was assessed and considered to be indicative of the treatment efficacy.



There were no differences in the demographic data between the treatment groups in any of the pretreatment measurements.

#### Assessment of the vaginal estrogenic effect of FC-1271a

5

Table 1 below shows the change in maturity index for parabasal cells (MI 1) and maturity index for superficial cells (MI 3), after 3 months' administration of varying doses of FC-1271a or raloxifene.

- 10 **Table 1.** Change in maturity index for parabasal cells (MI 1) and maturity index for superficial cells (MI 3), after 3 months' administration of varying doses of FC-1271a or raloxifene. (MI 1: index 100 no estrogenicity; index 0 full estrogen, and MI 3: index 100 full estrogen; index 0 no estrogenicity).

Compound and dose	MI 1 mean	MI 1 Sd	MI 3 mean	MI 3 15 sd
FC-1271a, 30 mg, (n=21)	-40	42	+12.4	13.6
FC-1271a, 60 mg, (n=20)	-26	39	+5.5	13.4
FC-1271a, 90 mg, (n=22)	-48	44	+12.5	14.0
Raloxifene, 60 mg, (n=19)	-2	34	-0.3	4.1

In Figures 1A to 1D there are shown changes (from start to 12 weeks' treatment) in the karyopyknosis index for superficial cells of the vaginal epithelium for the individuals treated daily with 30 mg FC-1271a (1A), 60 mg FC-1271a (1B), 90 mg FC-1271a (1C), and 60 mg raloxifene (1D).

5

Cervical smear assessments indicate that no one in the raloxifene group (fig. 1D) had a significant change from baseline to posttreatment in the karyopyknosis index for superficial cells. Most of the individuals in the FC-1271a groups had slight increases in the index, but in other subjects the estrogenic effect was very weak, if measurable at all. In all cases the increase was small (< 40 except for one case which was 45 in the 90 mg group) when compared to estradiol which is known to increase the index virtually by 100. A weak but statistically significant estrogenic effect in the cervical smear was therefore documented. No pathological changes were seen in any sample.

10  
15

Figure 2 shows that raloxifene caused only a minor decrease on vaginal dryness, assessed by the individuals' subjective estimate, while all the FC-1271a dosage levels indicated a clear decreasing effect. The dose level 60 mg FC-1271a daily gave the best result.

20

#### **Assessment of the endometrial estrogenic effect of FC-1271a**

FC-1271a had a weak estrogenic effect on endometrial histology. This effect is clearly weaker than that seen with estrogen replacement therapy. There were no malignant findings in the endometrium. The thickness of the endometrium as assessed by ultrasonography showed only a minor, statistically not significant, increase in the thickness (average 0.2 mm, 0.5 mm and 0.5 mm) at the dose levels of 30, 60 and 90 mg, respectively. The measured values were always smaller than 8 mm, which is considered to be a

25

thickness which is indicative for a physiologically significant estrogenicity of antiestrogenic drugs like tamoxifen (Hann et al, 1997; Lahti et al, 1993).

### **Effect on sexual activity**

5

In the clinical study, where the effects of FC-1271a on quality of life and cardiovascular parameters were studied, the patients were asked for sexual activity. The questionnaire included "worsening" or "no effect" on sexual activity. Improvement on sexual activity was not asked. When 70 patients had  
10 been followed up for 6 weeks, 27 of them had spontaneously reported to the investigators increased sexual activity. Similar reports were independently obtained from different centers of the study. This strongly suggests that FC-1271a has a positive effect on the sexual activity and quality of life.

15 The results indicate that FC-1271a has a unique pharmacological profile with regard to estrogen-like effects on vaginal dryness and insignificant endometrial effects. In the clinical study, FC-1271a has a weak estrogen-like activity in the vagina and uterus. In these tissues the estrogenicity is markedly lower than that of the known antiestrogens tamoxifen and toremifene, but  
20 higher than that of raloxifene. In contrast to other antiestrogens, it does not cause menopausal symptoms. Actually FC-1271a at the doses of 25 mg or more, and especially 30 - 90 mg daily, alleviated such symptoms. FC-1271a has an especially beneficial effect in that it decreases vaginal dryness and sexual dysfunction. Based on the present data, the optimal clinical dose is  
25 expected to be higher than 25 mg daily and lower than 100 mg daily. A particularly preferable daily dose is found in the range 30 to 90 mg. At the higher doses (100 and 200 mg daily), FC-1271a shows more antiestrogen-like properties and behaves almost like tamoxifen and toremifene. FC-1271a is an especially valuable drug because it has an excellent tolerability. In addition,  
30 FC-1271a decreases total and LDL cholesterol, increases HDL cholesterol,

and prevents osteoporosis and early stage breast cancer. The present invention suggests that FC-1271a can be also used during menopause as hormone replacement therapy instead of estrogens, which are known to increase the risk of breast and endometrium cancers.

5

It will be appreciated that the methods of the present invention can be incorporated in the form of a variety of embodiments, only a few of which are disclosed herein. It will be apparent for the specialist in the field that other embodiments exist and do not depart from the spirit of the invention. Thus,  
10 the described embodiments are illustrative and should not be construed as restrictive.

## REFERENCES

- Delmas PD, Bjarnason NH, Mitlak BH, Ravoux AC, Shah AS, Huster WJ, Draper M, Christiansen C: Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. *N Engl J Med* 337: 1641-1647, 1997
- Ettinger B, Genant HK, Cann CE: Long-term estrogen replacement therapy prevents bone loss and fractures. *Ann Intern Med* 102: 319-324, 1985
- Hann LE, Giess CS, Bach AM, Tao Y, Baum HJ, Barakat RR: Endometrial thickness in tamoxifen-treated patients: correlation with clinical and pathologic findings. *Am J Roentgenol* 168: 657-661, 1997
- Gustafsson J-Å: Estrogen receptor  $\beta$  - getting in on the action? *Nature Medicine* 3: 493-494, 1997
- Kangas L: Biochemical and pharmacological effects of toremifene metabolites. *Cancer Chemother Pharmacol* 27: 8-12, 1990
- Kauffman RF, Bryant HU: Selective estrogen receptor modulators. *Drug News Perspect* 8: 531-539, 1995
- Lahti E, Blanco G, Kauppila A, Apaja-Sarkkinen M, Taskinen PJ, Laatikainen T: Endometrial changes in postmenopausal breast cancer patients receiving tamoxifen. *Obstet Gynecol* 81: 660-664, 1993
- Palkowitz AD, Glasebrook AL, Thraser KJ, Hauser KL, Short LL, PhillipsDL, Muchi BS, Sato M, Shetler PK, Cullinan GJ, Pell TR, Bryant HU: Discovery and synthesis of [6-hydroxy-3-[4-[2-(1-

piperidinyloxy]phenoxy]-2-(4-hydroxyphenyl)]benzo[b]thiophene: a novel, highly potent, selective estrogen receptor modulator. *Med Chem* 40: 1407-1416, 1997

- 5 Payer L: The menopause in various cultures. In: *A portrait of the menopause. Expert reports on medical and therapeutic strategies for the 1990s*. Ed. Burger H & Boulet M, Parthenon Publishing, Park Ridge, NJ, USA, 1991. pp 3-22
- 10 Rekers H: Maturing the menopause. In: *A portrait of the menopause. Expert reports on medical and therapeutic strategies for the 1990s*. Ed. Burger H & Boulet M, Parthenon Publishing, Park Ridge, NJ, USA, 1991. pp 23-43
- Schneider LS, Finch CE: Can estrogens prevent neurodegeneration. *Drugs & Aging* 11: 87-95, 1997
- 15 Spector IP, Carey MP: Incidence and prevalence of sexual dysfunctions: a critical review of the empirical literature. *Archives of Sexual Behaviour* 19: 389-408, 1990.
- 20 Vuopala S, Kauppila A, Mikkonen M, Stenbäck F: Screening of asymptomatic postmenopausal women for gynecological malignancies, with special reference to endometrial sampling methods. *Arch Gynecol* 231: 119-127, 1982
- 25 Wakeling AE, Bowler J: Biology and mode of action of pure antiestrogens. *J Steroid Biochem* 30: 1-6, 1988

Wickelgren I: Estrogen stakes claim to cognition. *Science* 276: 675-678, 1997

## CLAIMS

1. A method for the treatment of vaginal dryness or sexual dysfunction in women during or after the menopause, said method comprising administering  
5 to the woman an effective amount of the compound  
(deaminohydroxy)toremifene or a pharmaceutically acceptable salt or ester thereof or metabolite thereof.
2. The method according to claim 1 wherein the compound or its salt or  
10 ester is administered in a daily dose varying in the range of 25 to 100 mg.
3. The method according to claim 2 wherein the compound or its salt or ester is administered in a daily dose varying in the range of 30 to 90 mg.
4. The method according to anyone of the claims 1 - 3 wherein the compound  
15 or its salt or ester is administered orally or transdermally.
5. The use of the compound (diaminohydroxy)toremifene or a pharmaceutically acceptable salt or ester or metabolite thereof for the  
20 manufacture of a pharmaceutical composition for the treatment of vaginal dryness or sexual dysfunction in women during or after the menopause.
6. The use according to claim 5 wherein the compound or its salt or ester is administered in a daily dose varying in the range of 25 to 100 mg.  
25
7. The use according to claim 6 wherein the compound or its salt or ester is administered in a daily dose varying in the range of 30 to 90 mg.
8. The use according to anyone of the claims 5 - 7 wherein the compound or  
30 its salt or ester is administered orally or transdermally.





1/2




FIG. 1A

FIG. 1B

FIG. 1C

FIG. 1D



2/2




Fig. 2



## INTERNATIONAL SEARCH REPORT

International application No.

PCT/FI 01/00414

## A. CLASSIFICATION OF SUBJECT MATTER

IPC7: A61K 31/085, A61P 15/12 // C07C 43/23  
According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC7: A61K, C07C

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-INTERNAL, WPI DATA, PAJ, CHEM.ABS DATA, BIOSIS, EMBASE, MEDLINE

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 9607402 A1 (ORIONHYTYMÄ OY), 14 March 1996 (14.03.96), page 1, line 6 - line 10; page 1, line 13 - line 14; page 1, line 22 - line 21, page 3, lines 10-30; page 13, lines 18-40, (Effect of (deaminohydroxy)toremifene on osteoporosis and association of osteoporosis with estrogenrelated mechanisms and the menopause)	1-8
A	Endocrinology -- Qu et al., Volume 141, No 2, 2000, Qiang Qu2 et al, "Selective Estrogenic Effects of a Novel Triphenylethylene Compound, FC1271a, on Bone, Cholesterol Level, and Reproductive Tissues in Intact and Ovariectomized Rats 1", page 809 - page 820, abstract (deaminohydroxy) toremifene is an estrogen agonist	1-8

☒ Further documents are listed in the continuation of Box C.

☒ See patent family annex.

* Special categories of cited documents:	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier application or patent but published on or after the international filing date	"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&" document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means	
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

Date of mailing of the international search report

22 October 2001

23 -10- 2001

Name and mailing address of the ISA/  
Swedish Patent Office  
Box 5055, S-102 42 STOCKHOLM  
Facsimile No. +46 8 666 02 86

Authorized officer

Per Renström/EÖ  
Telephone No. +46 8 782 25 00

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/FI 01/00414

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	Drugs, Volume 57, No 5, May 1999, Bruce H. Mitlak et al, "Selective Estrogen Receptor Modulators" page 653 - page 663 --	1-8
A	WO 9732574 A1 (ORION-YHTYMÄ OY), 12 Sept 1997 (12.09.97) --	1-8
E,X	EP 1125582 A2 (PFIZER PRODUCTS INC.), 22 August 2001 (22.08.01), abstract (Estrogen agonists, including the toremifene analog Droloxifene, for the treatment of sexual dysfunction) --	1-8
E,X	US 6245819 B1 (KAIJA HALONEN ET AL), 12 June 2001 (12.06.01), abstract, claims -- -----	1-8

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/FI 01/00414

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 1-4  
because they relate to subject matter not required to be searched by this Authority, namely:  
see next sheet
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.  
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.  
PCT/FI01/00414

Claims 1-4 relate to methods of treatment of the human or animal body by surgery or by therapy/ diagnostic methods practised on the human or animal body/Rule 39.1.(iv). Nevertheless, a search has been executed for these claims. The search has been based on the alleged effects of the compounds/compositions.



# INTERNATIONAL SEARCH REPORT

Information on patent family members

01/10/01

International application No.

PCT/FI 01/00414

Patent document cited in search report				Publication date		Patent family member(s)	Publication date
WO	9607402	A1	14/03/96	AT	183389	T	15/09/99
				AU	699845	B	17/12/98
				AU	3347895	A	27/03/96
				CA	2198389	A	14/03/96
				DE	69511566	D,T	27/04/00
				DK	779808	T	13/03/00
				EP	0779808	A,B	25/06/97
				SE	0779808	T3	
				ES	2135083	T	16/10/99
				FI	970920	A	04/03/97
				GB	9418067	D	00/00/00
				GR	3031109	T	31/12/99
				IL	115171	D	00/00/00
				JP	10505079	T	19/05/98
				NO	971037	A	29/04/97
				NZ	291836	A	26/06/98
				SI	779808	T	00/00/00
				US	5750576	A	12/05/98
				US	5912273	A	15/06/99
				ZA	9507481	A	09/04/96
WO	9732574	A1	12/09/97	AU	708336	B	05/08/99
				AU	2096897	A	22/09/97
				CA	2248032	A	12/09/97
				EP	0900077	A	10/03/99
				GB	9604577	D	00/00/00
				JP	2000506155	T	23/05/00
				US	6037379	A	14/03/00
EP	1125582	A2	22/08/01	AU	1112901	A	19/07/01
				HU	0100121	D	00/00/00
US	6245819	B1	12/06/01	NONE			

